Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

86.62 +1.46 (+1.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 Next >
2 Reasons to Avoid LMAT and 1 Stock to Buy Instead
Over the past six months, LeMaitre’s shares (currently trading at $83.18) have posted a disappointing 10.5% loss while the S&P 500 was down 4.1%. This may have investors wondering how to approach the... 
Via StockStory
Topics Stocks Supply Chain
Exposures Supply Chain US Equities
Winners And Losers Of Q4: Integra LifeSciences (NASDAQ:IART) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
Looking back on surgical equipment & consumables - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Integra LifeSciences (NASDAQ:IART) and its peers. 
Via StockStory
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
Q4 Earnings Review: Surgical Equipment & Consumables - Specialty Stocks Led by Intuitive Surgical (NASDAQ:ISRG)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including Intuitive... 
Via StockStory
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
Earnings Scheduled For February 27, 2025
Via Benzinga
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular
Via Benzinga
Analyst Scoreboard: 4 Ratings For LeMaitre Vascular
Via Benzinga
LeMaitre (NASDAQ:LMAT) Misses Q4 Sales Targets, Stock Drops 11%
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next quarter’s revenue guidance of... 
Via StockStory
What To Expect From LeMaitre’s (LMAT) Q4 Earnings
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results tomorrow after the bell. Here’s what to expect. 
Via StockStory
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Inari Medical Stock Gets RS Rating Upgrade
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth. 
Via Investor's Business Daily
Navigating 4 Analyst Ratings For LeMaitre Vascular
Via Benzinga
Recap: LeMaitre Vascular Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
This Synopsys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q2 2024
LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Staar Surgical Stock Earns RS Rating Upgrade
On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77. 
Via Investor's Business Daily
Stryker Stock Sees RS Rating Treks Higher To 71
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71. 
Via Investor's Business Daily
A Preview Of LeMaitre Vascular's Earnings
Via Benzinga
5 Analysts Have This to Say About LeMaitre Vascular
Via Benzinga
Sell In May And Go Away? – April Dividend Income Report
The “Sell in May and Go Away” adage is wrong for most investors. 
Via Talk Markets
LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q1 2024
LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Inspire Medical Systems Stock Sees IBD RS Rating Rise To 78
On Tuesday, Inspire Medical Systems stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 78. 
Via Investor's Business Daily
Barrington Research Maintains Outperform Rating for LeMaitre Vascular: Here's What You Need To Know
Via Benzinga
Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating
Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ: LMAT) with an Outperform rating and a  
Via Benzinga
Looking for Dividend Growth? Buy This Little-Known Healthcare Stock
The healthcare company's dividend has soared in recent years. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
2 Healthcare Stocks That Could Help Make You a Fortune
These companies did well for shareholders over the last 10 years and have the potential to keep the growth going. 
Via The Motley Fool
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.